Completed Genetics & Molecular Biology Infection & Immunity

Genomic Surveillance program for SARS-CoV-2: Consortium of India and Sri Lanka

In plain English

AI plain-English summary

A network of satellite genomic sequencing labs in India, Bangladesh and Sri Lanka will track new SARS-CoV-2 variants as they emerge in one of the world’s most densely populated regions. The problem is that high-quality viral surveillance has been concentrated in the UK, South Africa and Brazil, leaving large parts of South Asia without the capacity to detect local variants of concern before they drive fresh outbreaks. Without this data, public health responses and global R&D for diagnostics, vaccines and therapeutics are guided by an incomplete picture. If the network succeeds, it will create distributed local capacity through MicroLab hubs linked to national MegaLabs for quality assurance. Cloud-based workflows will integrate data across borders, giving researchers and health agencies real-time visibility into viral evolution. This directly supports the diagnostics and health systems pillars of the WHO’s ACT-Accelerator, helping to keep vaccine and treatment development aligned with the virus’s actual trajectory rather than lagging behind it.

View original technical description
The global challenges posed by COVID-19 are best tackled through global cooperation between researchers, clinicians and funding agencies. One such challenge is generating timely, high-resolution monitoring of the SARS-CoV-2 viral evolution and using such data to guide public health response in a timely manner. The discovery of current variants of concern (VOC) in UK, South Africa and Brazil is because of a high quality sequencing program (UK) or vaccination related investigations (South Africa, Brazil). Indian SARS-CoV-2 Genomic Consortia (INSACOG) is revealing the possibility of local VOC driving fresh outbreaks. We proposes a network of satellite genomic sequencing MicroLabs in India, Bangladesh and Sri Lanka that will be integrated by virtual cloud-based workflows as well as physical linkages to national MegaLabs for quality assurance and operational support. This would help scale up global monitoring of emerging SARS-CoV-2 strains in one of the world’s most populous region and guide global R&D efforts for COVID-19 diagnostics, vaccines and therapeutics. Given the relevance of SARS-CoV-2 surveillance to especially the diagnostics and health systems pillars of WHO’s ACT-Accelerator, partners such as Wellcome Trust can play an important role in furthering this effort. There is an urgent need to create distributed local capacity via MicroLab hubs.

View the original record at the funder ↗

Researchers

Anurag Agrawal (EPMC Awardee)VINOD SCARIA (EPMC Awardee)Vajira Dissanayake (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Leveraging COG-UK expertise to support the global dissemination of SARS-CoV-2 genome sequencing
Expansion and support of SARS-CoV-2 sequencing in West and Central Africa to support the COVID-19 pandemic response
NIHR Global Health Research Unit on Genomic Surveillance of Antimicrobial Resistance, University of Oxford
Genomic surveillance of SARS-CoV-2 and nationwide capacity building across Bangladesh
‘COVID-19 Genomics – MENA’: towards molecular surveillance of SARS-CoV-2 genomes during the vaccination period within the Middle East and North Africa

Original classification

Coronavirus

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.